Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heart bypass approach could mean faster recovery for patients

NCT ID NCT06794359

Disease control Sponsor: University of Sao Paulo General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a minimally invasive heart bypass surgery for people with blockages in multiple coronary arteries. Instead of opening the chest fully, surgeons work through a small incision on the left side. The goal is to see if this approach is safe and effective, with fewer complications and quicker recovery. About 100 adults with multi-vessel disease will take part, and researchers will track major events like death, heart attack, or stroke for up to 6 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Minimally invasive coronary artery bypass surgery (procedure)
What this could lead to
If successful, this could offer a less invasive alternative to traditional open-heart bypass surgery, potentially leading to faster recovery and fewer complications for patients with multi-vessel coronary disease.
What could go wrong
This is a small pilot study with only 100 participants, so results may not apply to all patients. The procedure is complex and may have risks like conversion to open surgery or major adverse events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients 18-years-old or older * Isolated myocardial revascularization procedure * Double or Triple-vessel disease with proximal or mid LAD disease with angiographic diameter stenosis \> 70% by visual analysis in all territories, requiring myocardial revascularization OR proximal LAD disease with angiographic diameter stenosis 50-70% by visual analysis in any territory but with invasive or non-invasive evidence of flow-limiting stenosis in all three territories, requiring myocardial revascularization * Total SYNTAX score \> 22 or low Syntax score unsuitable for PCI * Clinical and anatomic eligibility for both Minimally invasive and Conventional CABG surgery as agreed to by surgical team. * Silent ischemia, stable angina, unstable angina or recent MI \- If recent MI, cardiac biomarkers must have returned to normal prior to randomization * Ability to sign informed consent and comply with all study procedures Exclusion Criteria: * Reoperation * Need for any concomitant cardiac surgery other than CABG (e.g. valve surgery, aortic repair, etc.), or intent that if the patient randomizes to surgery, any cardiac surgical procedure other than isolated CABG will be performed * Left ventricle disfunction (EF\<40%) * Chronic Pulmonary obstructive disease * Renal failure disease * Emergency surgery * Obesity * Sternum anatomic defects including pectus excavatum * Peripheral vascular disease * Ascending aorta severe calcification * Non cardiac co-morbidities with life expectancy less than 1 year

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary arterial disease (CAD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary arterial disease (CAD) Coronary artery bypass

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • INCOR - Heart Institute from the University of Sao Paulo

    São Paulo, São Paulo, 05403900, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.